Soybean is used to support the estrogen body system primarily due to its content of isoflavones, which are classified as phytoestrogens—plant-derived compounds with estrogen-like activity. Scientific studies have shown that these isoflavones, particularly genistein and daidzein, can bind to estrogen receptors in the body, although their effects are weaker than endogenous estrogens. This has led to research into soy's potential effects on menopausal symptoms, bone health, and hormone-related conditions. Clinical trials suggest that soy isoflavones may modestly reduce the frequency and severity of hot flashes in menopausal women, though results are mixed and some studies show minimal benefit compared to placebo. Epidemiological data from populations with high soy consumption, such as in certain Asian countries, have also been interpreted as supporting a link to lower rates of hormone-dependent cancers, such as breast and prostate cancer, although causality is not firmly established. Regulatory agencies and scientific reviews generally conclude that soy isoflavones exert weak estrogenic effects and are safe for most populations, but they do not endorse soy as a replacement for hormone therapy. Thus, the use of soybean to support the estrogen body system is grounded in mechanistic plausibility and moderate clinical evidence, though the benefits are not robust or universal.